Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2022-07-04 Net Asset Value
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Net Asset Value Classification · 1% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC KEPLER CHEUVREUX" (Semi-annual balance sheet of the liquidity contract with Kepler Cheuvreux) and is dated July 4, 2022, reporting figures as of June 30, 2022. It details the status of a liquidity contract, comparing the current semi-annual figures (June 30, 2022) against the previous period's balance (December 31, 2021). This type of periodic report on a specific financial arrangement, often mandated by regulators like the AMF (mentioned in the text), fits the description of a comprehensive report for a period shorter than a year, which aligns best with the Interim / Quarterly Report (IR) category, although it is highly specific. Since it is a detailed balance sheet/report for a six-month period, it is more substantial than a simple Earnings Release (ER) or a mere announcement (RPA/RNS). The content is a detailed financial/contractual update covering a defined interim period (six months).
2022-07-04 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Share Issue/Capital Change Classification · 1% confidence The document is titled "*SUMMARY OF ONXEO'S LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX*" and provides detailed transactional data (executions, traded volume, shares held) related to a liquidity contract as of June 30, 2022, comparing it to December 31, 2021. It explicitly mentions compliance with the AMF Decision N°2021-01 regarding liquidity contracts. This type of regular disclosure concerning market making activities and share transactions by the company or its designated agent is typically classified as a report on transactions in own shares (share repurchase/issuance) or a specific regulatory filing. Given the detailed nature of the share transaction reporting (buy/sell side activity), it aligns best with the 'Transaction in Own Shares' category (POS), which covers share repurchase/issuance activities, even if this specific report details the status of a liquidity agreement rather than a direct buyback program announcement. It is a detailed report, not just an announcement of a report (ruling 2 does not apply). It is more specific than a general Regulatory Filing (RNS).
2022-07-04 English
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 30, 2022, announcing that Onxeo's Investigational New Drug (IND) application for AsiDNA was granted 'Study May Proceed' status by the U.S. FDA, allowing them to initiate a Phase 1b/2 trial. This type of announcement, detailing clinical trial progress, regulatory milestones, and business updates, is characteristic of an Earnings Release (ER) or a general press release. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, it best fits the 'Earnings Release' category, which often includes operational and clinical updates alongside financial highlights, or the general 'Regulatory Filings' (RNS) if it were purely regulatory. Given the focus on a major clinical/regulatory milestone announcement, ER is a strong candidate, but since it is not explicitly labeled as an 'Earnings Release' and is a general corporate update, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for significant, non-standardized corporate news that doesn't fit the other specific categories like M&A (TAR) or Capital Change (CAP). However, in many financial databases, major clinical trial updates are often grouped with ERs or IRs. Since this is a standalone announcement of a major operational event, and not a periodic financial report, RNS is the safest general classification for a non-standardized announcement.
2022-06-30 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 30, 2022, announcing that Onxeo received 'Study May Proceed' approval from the FDA for its Investigational New Drug (IND) application for AsiDNA. This announcement details clinical trial plans (Phase 1b/2) and provides company background. This type of announcement, which communicates a significant operational or regulatory milestone (like IND approval or clinical trial initiation) but is not a full financial report (like 10-K or IR) or a transcript, typically falls under a general regulatory announcement or an investor relations communication. Since it is a formal announcement of a key development, and not a specific financial report, capital change, or management change, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory update, or potentially an 'Earnings Release' (ER) if it were tied to a quarterly period, but the focus here is regulatory/clinical progress. Given the options, RNS serves as the best general regulatory/operational announcement category for non-standard filings.
2022-06-30 French
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document explicitly details the proceedings and outcomes of the 'Combined Shareholders' Meeting' held on June 15, 2022. Key elements include the adoption of resolutions, the appointment of a new Board member (Mr. Khalil Barrage), and comments from the Chairwoman regarding the meeting's results. This content directly relates to shareholder governance and the results of a general meeting. The most appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports the results of the votes taken at the meeting. It is not a full Annual Report (10-K), an Earnings Release (ER), or a proxy solicitation document (PSI), but rather the announcement of the results of the meeting itself.
2022-06-16 English
Informations privilégiées / Autres communiqués
AGM Information Classification · 1% confidence The document is titled "Onxeo : compte rendu de l'assemblée générale mixte du 15 juin 2022" (Onxeo: minutes/report of the mixed general meeting of June 15, 2022). It explicitly discusses the resolutions adopted by the shareholders, the ratification of a new board member (M. Khalil Barrage), and the renewal of another director's mandate. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Although it mentions the results of the votes will be available later, the core content is the report/summary of the meeting itself. This aligns best with the AGM Information category (AGM-R). It is not a proxy statement (PSI) as it reports the results, nor is it a general earnings release or annual report.
2022-06-16 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.